Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor in Chronic Neutropenia
NCT04154488Phase 2Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavorixafor in neutropenia, sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events After a Single Dose of Mavorixafor at 7 days, Number of Participants With Treatment-Emergent Adverse Events After Multiple Doses of Mavorixafor at 30 days and 2 more. Started Oct 2021; status: completed.
02
Drugs
mavorixafor
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04154488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154488.